We’re committed to working to empower you with the insights you need, so you can provide your patients with the answers and care they deserve. With blood and CSF testing methods, we offer one of the most comprehensive neurological testing portfolios in the industry.
Assess Alzheimer’s risk with a simple, accessible, and affordable blood test.
Quest is committed to expanding the QUEST AD-Detect portfolio of AD and dementia test offerings to support you and your patients through blood-based, easily accessible risk assessment options that can directly impact your care pathway.
QUEST AD-Detect™ Amyloid Beta 42/40 Ratio, Plasma
This test is used to assist in the differential diagnosis of AD1,2 and establishes a baseline and monitors over time. Our high-precision assay, using a simple blood sample, is the same type of assay shown to be as effective as traditional standard of care methods, such as cerebrospinal fluid (CSF) testing and amyloid positron emission tomography (PET) scans.3
QUEST AD-Detect™ Apolipoprotein (ApoE) Isoform
Apolipoprotein E (ApoE), the primary brain apolipoprotein, is a biomarker for AD that can be found in the blood or cerebral spinal fluid (CSF). The presence of an E4 allele is associated with both increased disease risk and decreased average age of onset compared with E2 or E3 alleles.
Can be ordered alongside other tests in the QUEST AD-Detect portfolio, such as QUEST AD-Detect Amyloid Beta 42/40, for a more robust risk assessment.
Powering better outcomes for your patients with memory loss
Quest and uMETHOD are redefining what’s possible for dementia and Alzheimer's patients.
At Quest, we know that some memory loss occurs as we get older, but dementia and Alzheimer’s disease are not a normal part of aging. While dementia is the #1 health concern of many retired people,4 only 1 in 7 of those 65 years or older are screened for memory loss.5
Quest is committed to bringing 2 powerful solutions together–uMETHOD's groundbreaking AI-based technology and our advanced lab testing–to help you analyze your patient’s risk factors and create a personalized care plan that can make a real difference.
Enhancing diagnostic specificity with the help of Phospho-Tau biomarkers
Alzheimer's can be difficult to diagnose. ADmark® Phospho-Tau/Total Tau/Aβ42 Analysis and Interpretation includes a set of 3 biomarkers that differentiates Alzheimer's disease (AD) from other forms of dementia.6
This panel combines results for Aβ42/40 ratio and ApoE into an algorithm to assess the cause of mild cognitive impairment (MCI) and the risk of AD.
Get the very latest news and information from Quest Advanced® Neurology.
About our tests links
1. Data on file. Quest Diagnostics; 2022.
2. Burnham SC, Fandos N, Fowler C, et al. Longitudinal evaluation of the natural history of amyloid-β in plasma and brain. Brain Commun. 2020;2(1)fcaa041. doi:10.1093/braincomms/fcaa041
3. Li Y, Schindler SE, Bollinger, J, et al. Validation of plasma amyloid-β 42/40 for detecting Alzheimer disease amyloid plaques. Neurology. 2022;98(7):e688–e699. doi:10.1212/
4. Edward Jones. The four pillars of the new retirement. 2020. Accessed May 13, 2021. https://www.edwardjones.com/sites/default/files/acquiadam/2021-01/Edward-Jones-4-Pillars-US-report.pdf
5. Sadler, AE. Does your doctor ask to test your memory? AARP. Epub March 5, 2019. Accessed May 13, 2021. https://www.aarp.org/health/dementia/info-2019/older-people-assessed-for-cognitive-issues.html
6. Hampel H, Buerger K, Zinkowski R, et al. Measurement of phosphorylated tau epitopes in the differential diagnosis of Alzheimer disease. Arch Gen Psychiatry. 2004;61(1):95-102. doi:10.1001/ archpsyc.61.1.95
Image content features a model and is intended for illustrative purposes only. Test codes may vary by location. Please contact your local laboratory for more information.